Education
About Us
Working with TipRanks
Follow Us
Edgewise Therapeutics (EWTX)
NASDAQ:EWTX
Total Valuation
Edgewise Therapeutics has a market cap or net worth of $3.21B. The enterprise value is $3.15B.
Market Cap$3.21B
Enterprise Value$3.15B
Share Statistics
Edgewise Therapeutics has 107,270,520 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding107,270,520
Owned by Insiders1.40%
Owned by Institutions8.09%
Financial Efficiency
Edgewise Therapeutics’s return on equity (ROE) is -0.32 and return on invested capital (ROIC) is -36.37%.
Return on Equity (ROE)-0.32
Return on Assets (ROA)-0.30
Return on Invested Capital (ROIC)-36.37%
Return on Capital Employed (ROCE)-0.36
Revenue Per Employee0.00
Profits Per Employee-1.43M
Employee Count117
Asset Turnover0.00
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Edgewise Therapeutics is ―. Edgewise Therapeutics’s PEG ratio is -1.23.
PE Ratio―
PS Ratio0.00
PB Ratio4.89
Price to Fair Value4.89
Price to FCF-17.76
Price to Operating Cash Flow-21.43
PEG Ratio-1.23
Income Statement
In the last 12 months, Edgewise Therapeutics had revenue of 0.00 and earned -167.79M in profits. Earnings per share was -1.63.
Revenue0.00
Gross Profit-2.27M
Operating Income-191.41M
Pretax Income-167.79M
Net Income-167.79M
EBITDA-165.53M
Earnings Per Share (EPS)-1.63
Cash Flow
In the last 12 months, operating cash flow was -143.82M and capital expenditures 0.00, giving a free cash flow of -143.82M billion.
Operating Cash Flow-143.82M
Free Cash Flow-143.82M
Free Cash Flow per Share-1.34
Dividends & Yields
Edgewise Therapeutics pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta2.25
52-Week Price Change18.43%
50-Day Moving Average28.26
200-Day Moving Average19.53
Relative Strength Index (RSI)53.83
Average Volume (3m)834.55K
Important Dates
Edgewise Therapeutics upcoming earnings date is May 7, 2026, After Close (Confirmed).
Last Earnings DateFeb 26, 2026
Next Earnings DateMay 7, 2026
Ex-Dividend Date―
Financial Position
Edgewise Therapeutics as a current ratio of 19.85, with Debt / Equity ratio of 0.76%
Current Ratio19.85
Quick Ratio19.85
Debt to Market Cap<0.01
Net Debt to EBITDA0.35
Interest Coverage Ratio0.00
Taxes
In the past 12 months, Edgewise Therapeutics has paid 0.00 in taxes.
Income Tax0.00
Effective Tax Rate0.00
Enterprise Valuation
Edgewise Therapeutics EV to EBITDA ratio is -15.09, with an EV/FCF ratio of -17.37.
EV to Sales0.00
EV to EBITDA-15.09
EV to Free Cash Flow-17.37
EV to Operating Cash Flow-17.37
Balance Sheet
Edgewise Therapeutics has $530.11M in cash and marketable securities with $3.99M in debt, giving a net cash position of $526.12M billion.
Cash & Marketable Securities$530.11M
Total Debt$3.99M
Net Cash$526.12M
Net Cash Per Share$4.90
Tangible Book Value Per Share$5.07
Margins
Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.
Gross Margin0.00%
Operating Margin0.00%
Pretax Margin0.00%
Net Profit Margin0.00%
EBITDA Margin0.00%
EBIT Margin0.00%
Analyst Forecast
The average price target for Edgewise Therapeutics is $39.33, which is 11.43% higher than the current price. The consensus rating is Strong Buy
Price Target$39.33
Price Target Upside26.91% Upside
Analyst ConsensusStrong Buy
Analyst Count9
Revenue Growth Forecast―
EPS Growth Forecast-5.73%